Results 1 to 10 of about 120,119 (188)

Anti-CTLA-4 Therapy for Malignant Mesothelioma [PDF]

Immunotherapy, 2017
Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to immunotherapy is immune checkpoint inhibitors, such as blockage of CTLA-4 and PD-1/PD-L1.
Guazzelli, A, Bakker, EY, Krstic-Demonacos, M, Lisanti, MP, Sotgia, F, Mutti, L   +5 more
openaire   +6 more sources

CTLA-4-Ig therapy preserves cardiac function following myocardial infarction with reperfusion. [PDF]

Cardiovasc Res
Noonan J, Prijaya SA, Bienvenu LA, Dayawansa NH, Michla M, Bongcaron V, Sharma P, Song Y, Huang A, Barbaro-Wahl A, Huang Y, Nguyen H, Nguyen A, Murphy AJ, Zhang Y, Lee MKS, Johnson CJ, Watson AMD, Thomas AC, McFadyen JD, Donner DG, Wang X, Peter K.   +22 more
europepmc   +2 more sources

Comparison of the intracellular trafficking itinerary of ctla-4 orthologues. [PDF]

, 2013
CTLA-4 is an essential inhibitor of T cell immune responses. At steady state, most CTLA-4 resides in intracellular compartments due to constitutive internalisation mediated via a tyrosine based endocytic motif (YVKM) within the cytoplasmic domain.
BJ Iacopetta, D Bernard, D Bernard, David M. Sansom, DM Sansom, E Chuang, H Ohno, H Schneider, JE Heuser, JG Egen, KI Mead, LS Walker, Omar S. Qureshi, OS Qureshi, OS Qureshi, P Waterhouse, Pierre Boudinot, PJ Lane, S Obermuller, Satdip Kaur, T Iida, T Shiratori, WA Teft, Y Zhang   +23 more
core   +17 more sources

Macrophages regulate PD-1 and CTLA-4 expression on ILC2s and their responsiveness in the tumor microenvironment. [PDF]

Cell Mol Immunol
Ciancaglini C, Santopolo S, Martini S, Scordamaglia F, Pietropaolo G, Laffranchi M, Sciumè G, Ferlazzo G, Vacca P, Moretta L, Quatrini L.   +10 more
europepmc   +3 more sources

Unraveling the role of Ctla-4 in intestinal immune homeostasis through a novel Zebrafish model of inflammatory bowel disease. [PDF]

Elife
Qin L, Hu C, Zhao Q, Wang Y, Fan D, Lin A, Xiang L, Chen Y, Shao J.   +8 more
europepmc   +2 more sources

Therapeutic options for CTLA-4 insufficiency

Journal of Allergy and Clinical Immunology, 2022
Heterozygous germline mutations in cytotoxic T lymphocyte-associated antigen-4 (CTLA4) impair the immunomodulatory function of regulatory T cells. Affected individuals are prone to life-threatening autoimmune and lymphoproliferative complications.
Egg, David, Rump, Ina Caroline, Mitsuiki, Noriko, Rojas-Restrepo, Jessica, Maccari, Maria-Elena, Schwab, Charlotte, Gabrysch, Annemarie, Warnatz, Klaus, Goldacker, Sigune, Patiño, Virginia, Wolff, Daniel, Okada, Satoshi, Hayakawa, Seiichi, Shikama, Yoshiaki, Kanda, Kenji, Imai, Kohsuke, Sotomatsu, Manabu, Kuwashima, Makoto, Kamiya, Takahiro, Morio, Tomohiro, Matsumoto, Kazuaki, Mori, Takeshi, Yoshimoto, Yuri, Dybedal, Ingunn, Kanariou, Maria, Kucuk, Zeynep Yesim, Chapdelaine, Hugo, Petruzelkova, Lenka, Lorenz, Hanns-Martin, Sullivan, Kathleen E, Heimall, Jennifer, Moutschen, Michel, Litzman, Jiri, Recher, Mike, Albert, Michael H, Hauck, Fabian, Seneviratne, Suranjith, Pachlopnik Schmid, Jana, Kolios, Antonios, Unglik, Gary, Klemann, Christian, Snapper, Scott, Giulino-Roth, Lisa, Svaton, Michael, Platt, Craig D, Hambleton, Sophie, Neth, Olaf, Gosse, Geraldine, Reinsch, Steffen, Holzinger, Dirk, Kim, Yae-Jean, Bakhtiar, Shahrzad, Atschekzei, Faranaz, Schmidt, Reinhold, Sogkas, Georgios, Chandrakasan, Shanmuganathan, Rae, William, Derfalvi, Beata, Marquart, Hanne Vibeke, Ozen, Ahmet, Kiykim, Ayca, Karakoc-Aydiner, Elif, Králíčková, Pavlína, de Bree, Godelieve, Kiritsi, Dimitra, Seidel, Markus G, Kobbe, Robin, Dantzer, Jennifer, Alsina, Laia, Armangue, Thais, Lougaris, Vassilios, Agyeman, Philipp, Nyström, Sofia, Buchbinder, David, Arkwright, Peter D, Grimbacher, Bodo   +75 more
openaire   +9 more sources

No association of CTLA-4 polymorphisms with susceptibility to Behcet disease [PDF]

, 2009
Background: Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a key negative regulator of T lymphocytes and has been shown to be associated with a number of autoimmune diseases. The present study was performed to assess the association between CTLA-
Du, L., Hou, S., Kijlstra, A., Yang, P., Zhou, H.   +4 more
core   +2 more sources

Anticorps anti-CTLA-4 [PDF]

médecine/sciences, 2011
L’immunotherapie par anticorps anti-CTLA-4, ipilimumab, est un traitement efficace du melanome metastatique utilise en monotherapie ou associe a la chimiotherapie (dacarbazine). L’effet therapeutique ne s’observe que chez 10 % a 20 % des patients, mais c’est la premiere fois qu’un medicament a un effet benefique sur la survie globale dans ce contexte ...
Caroline Robert, Christine Mateus
openaire   +1 more source

Immune checkpoints in circulating and tumor-Infiltrating CD4 + T Cell Subsets in Colorectal cancer patients [PDF]

, 2019
Blockade of inhibitory immune checkpoints (ICs) is a promising therapeutic approach; however, it has shown limited success in some cancers including colorectal cancer (CRC). The tumor microenvironment (TME) is largely responsible for response to therapy,
Abu Nada, M, Al-Dhaheri, M, Elkord, E, Khawar, M, Murshed, K, Toor, SM   +5 more
core   +2 more sources

Tolerance without clonal expansion: Self-antigen-expressing B cells program self-reactive T cells for future deletion [PDF]

, 2008
B cells have been shown in various animal models to induce immunological tolerance leading to reduced immune responses and protection from autoimmunity.
Anderton, Stephen M., Bettelli, Estelle, Buch, Thorsten, Frommer, Friederike, Heinen, Tobias J. A. J., Mueller, Werner, Roers, Axel, Waisman, Ari, Wunderlich, F. Thomas, Yogev, Nir   +9 more
core   +1 more source